Subscribe
shutterstock_580492693_akedesign
akedesign / Shutterstock.com
10 December 2020Big PharmaMuireann Bolger

90% of essential medicines off-patent, study reveals

Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.
Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.


Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025

More on this story

Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.
Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

More on this story

Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.
Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

More features

Amy Candido joins Simpson Thacher to head ‘powerhouse litigation team’
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
The rise of weight loss drugs: Regulators tighten up
Paul Hastings adds Latham tech transactions expert as co-chair
Why Abbott’s victory marks a turning point for UPC preliminary injunctions
Natera loses $96m jury win as judge invalidates DNA test patents
Fed Circ’s Wuhan v ITC ruling opens ITC door to small corps
Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules